At least it seems like NP must be more confident than for CD10 data, which was not sent for EUA after discussion with FDA. It's possible that there is something else going on other in their decision other than strength of supporting data, but it's hard to infer what that might be: restless investors? I think they are going by what many consultants see as a nice signal of efficacy in those getting other treatments and in those with critical disease (esp. younger).

Can't get EUA if one doesn't ask, so why not?